Information on results of RFP - 027311 - REFERENCE PRODUCTS

In connection with the implementation of the following projects: 

• Project “Development, clinical confirmation of bioequivalence and implementation of a new generation combination ternary inhalation drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00011 – 00 
• Project  “Development, clinical confirmation of bioequivalence and implementation of a new generation combination inhaled drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00012 – 00 
• Project “Development, clinical confirmation of bioequivalence and implementation of a new generation complex inhaled drug in the systematic therapy of respiratory diseases Asthma and COPD”, contract number 2022/ABM/04/00013 – 00 

financed from the state budget by the Agencja Badań Medycznych (Medical Research Agency) under the Call for Proposals for the development of innovative solutions in the field of new pharmaceutical forms of medicinal products authorized for marketing, generic medicines and biosimilar medicines ABM/2022/4, pursuant to § 8(2)(2) of the Grant Agreement, Adamed Pharma S.A. hereby informs that the contract will be awarded to: Pro Pharmaceuticals Group.